Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05796440 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Long-Term Safety Trial of LUM-201 in Children With Idiopathic Growth Hormone Deficiency Who Have Previously Completed a LUM-201 Clinical Trial (OraGrowtH211)

Study acronym: OraGrowtH211
StatusEnrolling by Invitation
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study completion date: Nov 2028 to Apr 2028v8
  2. Study sites: 2 to 7v7
  3. Study sites: 1 to 2v6
  4. Trial status: Not Yet Recruiting to Enrolling by Invitation
    • Study sites: 0 to 1
    v5
  5. Start date: May 2023 to Aug 1, 2023v4
Show 2 earlier versionsHide 2 earlier versions
  1. Study description revisedv3
  2. Study title expanded, about 1 wordv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a multi-national trial. The trial aims to study the long-term safety of LUM-201 in subjects with Idiopathic Pediatric Growth Hormone Deficiency (iPGHD). This study will also assess pharmacodynamics and efficacy response to therapy with LUM-201.
Trial Details
NCT Number NCT05796440
Lead Sponsor Lumos Pharma
Conditions
(from sponsor)		 Growth Hormone Deficiency
Related terms Dwarfism, Pituitary
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov